Biofluidica announced the results of a breast cancer study comparing invasive needle biopsies with their non-invasive, highly sensitive Next-Generation Liquid Biopsy platform, LiquidScan™ to...
BioFluidica, Inc., a biotechnology company developing a diagnostic platform allowing for disease management and diagnosis, today announced that it has raised over $6 million...
